Replies to post #210022 on Biotech Values

[DewDiligence]

SNY/REGN—FDA approves Dupixent (dupilumab) for moderate-to-severe atopic dermatitis:

http://finance.yahoo.com/news/sanofi-regeneron-announce-fda-approval-154000321.html

The PDUFA date was tomorrow.

Dupixent works by inhibiting IL-4 and IL-13. In the US, Dupixent will be co-marketed by SNY and REGN.

[DewDiligence]

AMGN countersues SNY/REGN on Dupixent:

http://www.fiercepharma.com/pharma/amgen-already-pcsk9-offense-slaps-sanofi-regeneron-dupixent-patent-suit